Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Robert F. Kennedy Jr. has pledged to tackle high rates of chronic diseases such as diabetes and obesity as President-elect ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

The impact of expanding access to GLP-1 receptor agonists, dual gastric inhibitory polypeptide and GLP-1 receptor agonists quantified. HealthDay News — Expanding access to obesity medications such as ...

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports today.

THURSDAY, Nov. 7, 2024 (HealthDay News) -- Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor ...